Indianapolis, IN, United States of America

Matthew Robert Reinhard



 

Average Co-Inventor Count = 11.0

ph-index = 2

Forward Citations = 11(Granted Patents)


Company Filing History:


Years Active: 2005-2015

Loading Chart...
Loading Chart...
Loading Chart...
7 patents (USPTO):Explore Patents

Title: Matthew Robert Reinhard: Pioneering Innovator in Pharmaceutical Developments

Introduction: Matthew Robert Reinhard, a prolific inventor based in Indianapolis, IN, holds a remarkable tally of 7 patents, showcasing his ingenuity in the field of pharmaceuticals. His groundbreaking inventions are revolutionizing the treatment of various neurological and psychiatric conditions.

Latest Patents:

1. Reinhard's patent introduces novel 3,4-dihydroisoquinolin-2(1H)-yl compounds for addressing cognitive impairment linked to Parkinson's disease or schizophrenia. These compounds of formula I exhibit promising pharmaceutical properties.

2. Another cutting-edge patent by Reinhard unveils 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines as selective 5-HT2c receptor agonists, offering new avenues for treating disorders like obesity, obsessive/compulsive disorder, depression, and anxiety.

Career Highlights: Matthew Robert Reinhard is a key figure at Eli Lilly and Company, a renowned pharmaceutical giant known for its trailblazing research and product development in the healthcare industry. Reinhard's innovative contributions have cemented his status as a visionary in the pharmaceutical sector, driving advancements that positively impact patient care worldwide.

Collaborations: Reinhard collaborates closely with esteemed colleagues at Eli Lilly and Company, such as Karin Briner and Christopher Stanley Galka. Together, they form a dynamic team dedicated to pushing the boundaries of pharmaceutical innovation and improving therapeutic options for diverse medical conditions.

Conclusion: Matthew Robert Reinhard's inventive prowess and strategic collaborations at Eli Lilly and Company underscore his pivotal role in shaping the future of pharmaceutical advancements. His patents stand as testaments to his dedication to enhancing treatment modalities for complex neurological and psychiatric disorders, embodying a commitment to driving positive change in healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…